| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
HDAC1
The primary target of 9-Hydroxyoctadecanoic acid is histone deacetylase 1 (HDAC1). It functions as an HDAC1 inhibitor that inhibits approximately 66.4% of HDAC1 enzymatic activity at 5 μM. By inhibiting HDAC1, it modulates gene expression and exhibits anticancer activity. The compound does not have a defined receptor target but exerts its effects through epigenetic modulation and enzyme inhibition. |
|---|---|
| ln Vitro |
In the three-dimensional model of the human HDAC1 protein, 9-Hydroxyoctadecanoic acid (9-HSA) can bind to the active site [1]. Increased transcription and translation of p21WAF1 is observed upon exposure to 100 μM of 9-Hydroxyoctadecanoic acid (9-HSA) over 24 hours, which also causes G0/G1 arrest and reduces the proliferation of HT29 cells [2].
In vitro, 9-Hydroxyoctadecanoic acid (9-HSA) is an HDAC1 inhibitor that inhibits ∼66.4% HDAC1 enzymatic activity at 5 μM. The compound shows anticancer activity. It is formed from 9-PAHSA by liver and pancreatic carboxyl esterases. The compound's HDAC1 inhibitory activity is concentration-dependent and has been characterized in biochemical enzyme assays. |
| ln Vivo |
In vivo activity of 9-Hydroxyoctadecanoic acid has not been extensively characterized. As a bioactive hydroxy fatty acid, it has been investigated for its potential anti-inflammatory, antimicrobial, and antioxidant properties. It may also have applications in the development of functional foods, cosmetics, and pharmaceutical products due to its beneficial effects on skin health and inflammation management. However, detailed in vivo pharmacokinetic and pharmacodynamic studies are limited.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 9-Hydroxyoctadecanoic acid typically involve HDAC1 inhibition studies. The enzyme is incubated with varying concentrations of the compound (e.g., 5 μM) in appropriate buffer at 37°C. HDAC1 enzymatic activity is measured using fluorogenic substrates, and the percentage inhibition is calculated from the dose-response curve. The compound demonstrates concentration-dependent inhibition of HDAC1 activity.
|
| Cell Assay |
Cell Proliferation Assay[1].
Cell Types: HT29 cell Tested Concentrations: 100 μM Incubation Duration: 24 h Experimental Results: Resulted in a significant inhibition of cell proliferation. Cell Cycle Analysis[1]. Cell Types: HT29 cell Tested Concentrations: 100 μM Incubation Duration: 24 h Experimental Results: diminished S-phase activity by 50.2% compared with untreated controls, and the growth inhibition was associated with a strong arrest in G0/G1. Western Blot Analysis[1]. Cell Types: HT29 cell Tested Concentrations: 100 μM Incubation Duration: 24 h Experimental Results: Increased the expression of p21WAF1. RT-PCR[1]. Cell Types: HT29 cell Tested Concentrations: 100 μM Incubation Duration: 24 h Experimental Results: Induced p21WAF1 tanscript. In vitro cellular assays for 9-Hydroxyoctadecanoic acid involve testing its anticancer activity. Cancer cell lines are treated with serial dilutions of the compound, and cell viability is assessed using MTT or CCK-8 assays after 48-72 hours. The compound's HDAC1 inhibitory activity is also evaluated by measuring histone acetylation levels in treated cells via Western blot. The compound demonstrates concentration-dependent anticancer activity. |
| Animal Protocol |
In vivo animal studies for 9-Hydroxyoctadecanoic acid are limited, as the compound is primarily studied in vitro. For efficacy testing, animal models of inflammation or cancer could be used. Animals would be treated with the compound via oral or intraperitoneal administration at various doses, and relevant biomarkers would be assessed. However, detailed in vivo protocols are not well established for this compound, and most studies have focused on in vitro characterization.
|
| ADME/Pharmacokinetics |
9-Hydroxyoctadecanoic acid has a molecular formula of C18H36O3 and a molecular weight of 300.48. It appears as a white to off-white solid powder with a purity of ≥98.0%. The compound is a long-chain hydroxy fatty acid. Information concerning product stability, particularly in solution, has rarely been reported and in most cases only a general guide can be offered. It is intended for research use only and is not for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 9-Hydroxyoctadecanoic acid has not been extensively characterized. As a naturally occurring fatty acid derivative, it is generally considered to have low toxicity. Standard toxicity studies would include assessment of acute oral toxicity, dermal irritation, and repeated-dose toxicity in animal models. The compound is intended for research use only and is not approved for clinical use.
|
| References | |
| Additional Infomation |
9-Hydroxyoctadecanoic acid is a hydroxyoctadecanoic acid formed by replacing the hydroxyl group at the 9th position of octadecanoic acid (stearic acid). It is the conjugate acid of 9-hydroxyoctadecanoate.
9-Hydroxyoctadecanoic acid (CAS 3384-24-5) has a molecular formula of C18H36O3 and a molecular weight of 300.48. It is a hydroxy fatty acid and an active metabolite of 9-PAHSA. The compound is a bioactive compound found in various plant and animal tissues and has been investigated for its potential anti-inflammatory, antimicrobial, and antioxidant properties. It is an HDAC1 inhibitor that inhibits ∼66.4% HDAC1 enzymatic activity at 5 μM and shows anticancer activity. It is intended for research use only and is not approved for clinical use. |
| Molecular Formula |
C18H36O3
|
|---|---|
| Molecular Weight |
300.48
|
| Exact Mass |
300.266
|
| CAS # |
3384-24-5
|
| PubChem CID |
9570127
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.303
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
21
|
| Complexity |
229
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
RKHXDCVAPIMDMG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H36O3/c1-2-3-4-5-6-8-11-14-17(19)15-12-9-7-10-13-16-18(20)21/h17,19H,2-16H2,1H3,(H,20,21)
|
| Chemical Name |
9-hydroxyoctadecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (332.80 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3280 mL | 16.6400 mL | 33.2801 mL | |
| 5 mM | 0.6656 mL | 3.3280 mL | 6.6560 mL | |
| 10 mM | 0.3328 mL | 1.6640 mL | 3.3280 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
